Add BrightSurf on Google Email

Med-X | Biomaterial-based immunomodulation opens new avenues for cardiac repair and regeneration

11.12.26 | Shanghai Jiao Tong University Journal Center

Myocardial infarction (MI) remains a major cause of cardiovascular morbidity and mortality worldwide. Although current treatments, including coronary revascularization and pharmacological interventions, can restore blood flow and limit acute myocardial injury, the adult human heart has a limited capacity for regeneration. Consequently, extensive cardiomyocyte loss and persistent inflammation often lead to fibrosis, adverse ventricular remodeling, and ultimately heart failure. Increasing evidence suggests that immune responses play a dual role in this process, contributing to both tissue injury and subsequent repair. Recent advances in biomaterials and regenerative medicine are creating new opportunities to precisely regulate the cardiac immune microenvironment and promote functional recovery after MI.

Recently, a comprehensive review titled "Harnessing biomaterial-based immunomodulation for cardiac repair and regeneration" was published in Med-X . The review systematically summarizes the immune mechanisms involved in myocardial injury and repair, highlights emerging biomaterial-mediated immunomodulatory strategies, including nanoparticle delivery systems, injectable hydrogels, and implantable cardiac patches, and discusses their potential for advancing cardiovascular regenerative medicine.

1. Immune Regulation: A Critical Determinant of Cardiac Injury and Repair

Following MI, damaged cardiomyocytes release inflammatory signals that trigger the recruitment of neutrophils, monocytes, and macrophages to the injured myocardium. During the early inflammatory phase, these immune cells remove cellular debris but may also exacerbate tissue damage through the release of inflammatory cytokines and reactive oxygen species. As healing progresses, reparative macrophages and regulatory immune cells help resolve inflammation, promote angiogenesis, and coordinate tissue remodeling. However, persistent or excessive inflammation can disrupt this balance, leading to pathological fibrosis and impaired cardiac function. These dynamic immune responses highlight the importance of precisely controlling the timing, location, and intensity of immunomodulation rather than broadly suppressing inflammation.

2. Nanoparticle Delivery Systems: Enabling Targeted Immunomodulation

To address the limitations of conventional anti-inflammatory therapies, nanoparticle-based delivery systems have emerged as promising tools for targeted cardiac immunomodulation. Through controlled particle design and surface functionalization, nanocarriers can improve the delivery of therapeutic molecules to injured myocardial tissue and specific immune cell populations. Targeted nanoparticles can enhance drug accumulation at inflammatory sites, while stimuli-responsive systems exploit local pathological conditions, such as elevated reactive oxygen species, altered pH, or enzyme activity, to achieve controlled therapeutic release. In addition, engineered extracellular vesicles and biomimetic nanoparticles utilize natural cellular components to improve biological compatibility and targeting efficiency. These approaches have demonstrated potential to reduce excessive inflammation, promote reparative macrophage responses, and improve cardiac recovery in preclinical models.

3. Injectable Hydrogels: Supporting Localized and Sustained Cardiac Repair

Beyond nanoscale delivery systems, injectable hydrogels provide a versatile platform for localized immunomodulation and cardiac tissue repair. Their hydrated, three-dimensional networks can mimic aspects of the extracellular matrix while enabling the sustained release of therapeutic agents within injured myocardium. Stimuli-responsive hydrogels can adapt to the inflammatory microenvironment and release immunomodulatory molecules in response to disease-associated signals. Meanwhile, microgel-based systems and hydrogels incorporating stem cells, extracellular vesicles, or their derivatives can enhance therapeutic retention and support regenerative signaling. By combining localized drug delivery with structural support and biological activity, these systems offer opportunities to reduce inflammation, limit fibrosis, and promote myocardial repair through minimally invasive approaches.

4. Implantable Cardiac Patches: Integrating Immunomodulation with Tissue Engineering

For more extensive myocardial injury, implantable cardiac patches offer an alternative strategy that combines therapeutic delivery with mechanical and structural support. Advances in three-dimensional bioprinting, electrospinning, and microneedle technologies have enabled the fabrication of functional patches designed to interact with damaged cardiac tissue. These platforms can incorporate immunomodulatory agents, growth factors, and therapeutic cells to regulate local inflammation, support angiogenesis, and improve tissue remodeling. Furthermore, adhesive and conductive patches may help restore mechanical integration and electrical communication within injured myocardium. By integrating immunomodulation with cardiac tissue engineering, these approaches provide promising opportunities for improving cardiac repair, although their clinical translation remains limited by implantation requirements and long-term safety considerations.

5. Scholarly Value and Future Perspectives

This review highlights the potential of integrating biomaterials engineering with precision immunomodulation to improve cardiac repair and regeneration after MI. Nanoparticles, injectable hydrogels, and cardiac patches offer complementary strategies for controlling immune responses across different stages of myocardial healing. Future progress will depend on improving tissue-specific targeting, optimizing treatment timing, and addressing challenges related to biocompatibility, manufacturing scalability, and clinical safety. By connecting cardiac immunology with advanced drug delivery and tissue engineering, the review provides valuable insights into the development of more effective and personalized regenerative therapies for cardiovascular diseases.

Med-X

10.1007/s44258-026-00094-6

News article

Harnessing biomaterial-based immunomodulation for cardiac repair and regeneration

28-Sep-2026

Keywords

Article Information

Contact Information

Bowen Li
Shanghai Jiao Tong University Journal Center
qkzx@sjtu.edu.cn

Source

This article is based on a news release from Shanghai Jiao Tong University Journal Center. BrightSurf curates and republishes science news from research institutions worldwide; the original release is linked below.

How to Cite This Article

APA:
Shanghai Jiao Tong University Journal Center. (2026, November 12). Med-X | Biomaterial-based immunomodulation opens new avenues for cardiac repair and regeneration. Brightsurf News. https://www.brightsurf.com/news/8OMXZZN1/med-x-biomaterial-based-immunomodulation-opens-new-avenues-for-cardiac-repair-and-regeneration.html
MLA:
"Med-X | Biomaterial-based immunomodulation opens new avenues for cardiac repair and regeneration." Brightsurf News, Nov. 12 2026, https://www.brightsurf.com/news/8OMXZZN1/med-x-biomaterial-based-immunomodulation-opens-new-avenues-for-cardiac-repair-and-regeneration.html.